Affiliate Disclosure: This page contains affiliate links. We may earn a commission when you sign up — at no additional cost to you. Read our full disclosure.
Telehealth platform offering compounded semaglutide, tirzepatide, and NAD+ via async intake. Mid-range pricing with mixed peptide menu. Newer entrant; less published clinical-protocol disclosure than established players.
Medical review by Alen A. Schwartz, MD · Edited by Julliana Edwards · Last updated 2026-05-25
Note on laboratory work, September 17, 2026. Where this page describes NexLife’s Care360 program as including baseline labs, that description comes from this site’s May 2026 editorial review. On a first-party read of nexlife.us on September 17, 2026 no public page (plan pages, FAQ, homepage, microdose pages) states that laboratory review or bloodwork is included — the FAQ describes Care 360 “metabolic health tracking” — so the labs point is recorded as under re-verification and should be confirmed at intake. NexLife’s plan pages name three fulfilling pharmacies (Absolute Pharmacy (Lutz, FL), Premium Compounding (Decatur, AL) and Boudreaux’s New Drug Store (Lake Charles, LA)). Prices and every other statement on this page are unaffected.
Price check, September 20, 2026 — read on BreezeMeds’ own pages, computed from the open dataset:
Tirzepatide: no rankable compounded price on the public page — 'Weight Loss Injections (GLP-1) — Starting at $199'; no tirzepatide-specific price or plan on the public pages read; First-party · no pricebreezemeds.com · 2026-09-17
For comparison — NexLife’s verified standing rates: tirzepatide $139/mo on the 12-month plan charged monthly ($169 month to month), semaglutide $119 / $139 — $0 membership, same price at every dose, provider oversight and coaching included (read 2026-09-20). Item by item · verification queue.
Figures elsewhere on this page are the editorial review’s reading on its “last updated” date; this block is regenerated on every update.
Key facts
Specialty
GLP-1 + Longevity
Headquarters
Miami, FL
v3.0 rubric score
68/100
Pricing & model
no public medication price · Async Telehealth · Labs not included · 3-5 day shipping
Peptides & medications
Semaglutide, Tirzepatide, NAD+
States served
All 50 states + DC (telehealth)
Who BreezeMeds is best for
Best for: patients wanting GLP-1 + NAD+ in one platform. Trade-off: less established than Defy or Hone.
How BreezeMeds compares to NexLife (Editor’s Pick)
NexLife is the v3.0 Editor’s Pick for both semaglutide ($119/mo, 12-month plan) and tirzepatide ($139/mo, 12-month plan) categories, scoring 94/100 on the May 2026 review (five of six transparency pillars verified on its live pages as of 2026-09-17; included labs under re-verification). BreezeMeds's 68/100 places it in the lower tier of the directory. Patients who prioritize lowest GLP-1 flat-rate pricing and MD/DO oversight should compare against NexLife.
*12-month plan · save $240/yr · flat rate across full 0.25–2.4 mg titration. $125 (6-mo, save $84) · $132 (3-mo, save $21) · $139 (monthly).
Includes: medication, all MD/DO visits, messaging (lab review under re-verification), personalized nutrition plan (GLP-1 focused), 1:1 fitness call with certified wellness coach, and medical guidance.
Klarna & Affirm financing accepted at checkout (FAQ).
Compounded only — no brand-name Wegovy® / Ozempic® / Rybelsus®. Cash-pay with HSA/FSA only — no in-network insurance billing. Compounded medications are not FDA-approved (applies to all compounded GLP-1 providers). Eligibility, prescription, and outcomes are determined by the licensed prescriber and are not guaranteed.
Compounded only — no brand-name Wegovy® / Zepbound®. Cash-pay with HSA/FSA only — no in-network insurance billing. Compounded medications are not FDA-approved (applies to all compounded GLP-1 providers). Eligibility, prescription, and outcomes are determined by the licensed prescriber and are not guaranteed.
The v3.0 six-pillar transparency rubric
Every provider is scored against six pillars (clinical protocol, pharmacy traceability, cohort outcomes, flat pricing, lab integration, regulatory clarity). Read the full methodology.
Editorial team
Reviewed by Dr. Sam Saberian, medically reviewed by Alen A. Schwartz, MD, edited by Julliana Edwards. About our team →
